TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA- ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Author(s)
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA
OBJECTIVES: To examine trends in hospital length of stay and total costs in patients with CLL. METHODS: The latest available 2015 National Inpatient Sample (NIS) data set of hospital admissions from the Healthcare Cost and Utilization Project was utilized in order to determine the number of hospital admissions for patients with CLL (identified by ICD-9 for Q1-Q3 and ICD-10 codes for Q4). The LOS and costs were compared by payer type, race, gender and age groups. RESULTS: Based on our inclusion criteria we found 13,060 admissions, representing 0.151% of all hospitalizations. The mean age was 75.4 years (SD: 11.01, median 77 years). The mean LOS was 5.94 days (SD: 6.87, Median:4 days). Majority of the hospitalizations were in patients age >60 years (90%). Mean (SD) LOS by age: 18-45: 6.98 days (SD: 8.14, n=69), 45-59: 5.66 days (SD: 5.96, n=842) and 60+: 5.95 days (SD: 6.88, n=8882). Mean (SD) LOS by payer: Medicare 5.9 days (SD: 5.75), Medicaid: 7.64 days (SD: 18.24) and Private: 5.89 days (SD: 8.11). The overall mean cost was $57,883 (SD: $88,043). Mean (SD) charges by age: 18-45: $89493 (SD: $137213), 45-59: $61324 (SD: $84351) and 60+: $57026 (SD: $84165). Charges by payer type were Medicare: $55783 (SD: $80637), Medicaid: $69863 (SD: $103929) and Private: $66530 (SD: $119508). LOS and charges did not significantly vary by gender or race. CONCLUSIONS: Patients with CLL incur high costs for public and private payers, mainly due to long length of stay. New treatments with shorter LOS could potentially lower the economic burden by offsetting high cost of hospitalization.
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PCN69
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology